introduct
ag
respistrip
immunochromatograph
ict
assay
rapid
detect
antigen
nasopharyng
specimen
develop
identifi
posit
patient
allow
prompt
clinic
quarantin
decis
origin
research
articl
describ
concept
analyt
clinic
perform
well
risk
manag
implement
ag
respistrip
diagnost
decis
algorithm
materi
method
develop
ag
respistrip
result
readytous
ict
assay
base
membran
technolog
colloid
gold
nanoparticl
use
monoclon
antibodi
direct
sarscov
highli
conserv
nucleoprotein
antigen
four
hundr
observ
record
analyt
perform
studi
thirti
test
analys
crossreact
studi
clinic
perform
studi
perform
retrospect
multicentr
evalu
aliquot
nasopharyng
sampl
ag
respistrip
result
compar
qrtpcr
golden
standard
diagnost
result
analyt
perform
studi
reproduc
show
betweenobserv
disagr
robust
overal
satisfi
user
friendli
crossreact
virusinfect
nasopharyng
sampl
clinic
perform
studi
perform
three
differ
clinic
laboratori
found
overal
sensit
specif
respect
accuraci
cutoff
assay
found
ct
userfriendli
analysi
risk
manag
assess
ishikawa
diagram
demonstr
ag
respistrip
may
implement
clinic
laboratori
accord
biosafeti
recommend
ag
respistrip
repres
promis
rapid
antigen
assay
firstlin
diagnosi
minut
role
propos
diagnost
algorithm
complementari
currentlyus
molecular
techniqu
sever
acut
respiratori
syndrom
coronaviru
repres
major
health
threat
humankind
absenc
vaccin
specif
antivir
treatment
contain
pandem
reli
mainli
rapid
identif
isol
patient
addit
chest
comput
tomographi
ct
strategi
base
avail
realtim
revers
transcript
polymeras
chain
reaction
qrtpcr
perform
suspect
patient
present
specif
symptom
symptom
similar
season
flu
current
possibl
test
patient
flulik
symptom
due
lack
resourc
avail
diagnost
test
mention
audio
interview
new
england
journal
medicin
th
march
import
establish
correct
diagnosi
central
give
appropri
care
patient
far
sever
molecularbas
test
develop
implement
laboratori
refer
centr
capabl
perform
test
see
http
detail
howev
avail
molecular
diagnost
test
concern
face
worldwid
shortag
reagent
although
molecular
diagnosi
sensit
specif
diagnost
method
need
materi
reagent
train
personnel
limit
number
assay
perform
satur
laboratori
moreov
qrtpcr
still
rapid
turnaround
time
tat
develop
rapid
diagnost
assay
allow
faster
confirm
clinic
suspicion
lead
earlier
isol
appropri
clinic
care
patient
posit
result
sever
serolog
test
develop
serolog
antibodydetect
assay
fulfil
requir
detect
earli
infect
averag
incub
period
day
short
develop
immun
respons
perspect
cori
bioconcept
belgian
manufactur
develop
immunochromatograph
assay
ict
rapid
detect
antigen
nasopharyng
specimen
minut
thank
result
previou
research
work
sarscov
nucleoprotein
identifi
best
target
sensit
diagnost
sandwich
assay
use
monoclon
antibodi
share
high
similar
bat
coronavirus
known
sarscov
epidem
provid
opportun
use
previous
develop
reagent
develop
rapid
diagnost
right
reserv
reus
allow
without
permiss
certifi
peer
review
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
version
post
april
http
assay
abl
also
detect
new
diagnost
techniqu
consist
antisarscov
captur
antibodi
fix
onto
nitrocellulos
strip
label
antisarscov
antibodi
migrat
buffer
sampl
regard
pandem
urgenc
share
relev
data
origin
research
articl
describ
analyt
perform
ag
respistrip
accord
requir
actual
european
direct
futur
european
regul
vitro
diagnost
ivd
medic
devic
scandinavian
skupprotocol
use
valid
qualit
test
clinic
perform
obtain
multicentr
retrospect
studi
addit
reflect
risk
manag
condit
fulfil
implement
pointofcar
test
poct
outsid
hospit
right
reserv
reus
allow
without
permiss
certifi
peer
review
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
version
post
april
http
antibodi
antigen
eleven
antibodi
design
k
coat
variou
concentr
nitrocellulos
advanc
microdevic
india
antibodi
j
coupl
colloid
gold
bead
nanoq
belgium
recombin
sarscov
nucleoprotein
recnp
prepar
obtain
describ
previous
coat
nitrocellulos
membran
conjug
colloid
gold
nanoparticl
recombin
histag
np
produc
insect
cell
purifi
purif
final
puriti
genscript
leiden
nl
ag
respistrip
ict
strip
consist
nitrocellulos
lamin
plastic
back
colloidalgold
conjug
dri
conjug
pad
franc
overlap
bottom
nitrocellulos
preliminari
direct
detect
sarscov
np
coat
goldlabel
antibodi
deposit
ag
respistrip
test
monoclon
antibodi
direct
sarscov
highli
conserv
nucleoprotein
antigen
coat
nitrocellulos
anoth
monoclon
antibodi
conjug
colloid
gold
nanoparticl
conjug
immobil
conjug
pad
develop
test
analys
antibodi
reactiv
intens
perform
use
serial
dilut
final
volum
buffer
data
shown
cfr
supplementari
materi
result
determin
min
standard
oper
procedur
ag
respistrip
follow
figur
transfer
nasopharyng
sampl
nasopharyng
aspir
nasopharyng
wash
nasalnasopharyng
swab
collect
tube
add
ly
dilut
buffer
reach
dilut
ratio
cap
tube
stopper
stir
thoroughli
homogen
solut
open
tube
immers
strip
direct
indic
close
tube
stopper
allow
react
minut
read
result
interpret
result
neg
test
result
reddishpurpl
line
appear
control
line
c
posit
upper
line
band
present
posit
test
result
addit
reddishpurpl
band
control
line
c
visibl
reddishpurpl
band
appear
test
line
posit
intens
test
line
may
vari
accord
quantiti
antigen
found
sampl
reddish
right
reserv
reus
allow
without
permiss
certifi
peer
review
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
version
post
april
http
purpl
line
even
weak
consid
posit
result
invalid
test
result
absenc
control
line
indic
failur
test
procedur
repeat
invalid
test
new
strip
discard
close
tube
accord
biohazard
rule
elisa
microtit
plate
coat
recnp
recombin
maltos
bind
protein
mbp
incub
overnight
plate
wash
water
wash
buffer
phosphatebuff
pbst
block
solut
milk
powder
ad
minut
block
solut
discard
mab
ad
pgml
block
solut
recnp
mbp
incub
hour
plate
wash
rabbit
antimous
igghrp
dako
ad
dilut
anoth
hour
incub
plate
wash
microlit
tmb
substrat
solut
ad
incub
took
place
room
temperatur
enzymat
reaction
stop
addit
n
light
absorpt
measur
photomet
nm
use
nm
refer
wavelength
measur
done
duplic
obtain
final
od
od
obtain
control
protein
mbp
subtract
od
obtain
recnp
viru
passag
access
nogenebank
cultur
vero
cell
titr
determin
use
plaqu
assay
describ
fixat
cell
experi
involv
isol
perform
biosafeti
level
laboratori
public
health
agenc
sweden
stockholm
sweden
qrtpcr
sampl
extract
use
directzol
rna
miniprep
kit
zymo
research
qrtpcr
run
use
egen
primersprob
follow
world
health
organ
advis
develop
phase
analyt
perform
first
perform
serial
dilut
cultur
viru
parallel
titter
viru
prepar
vero
cell
test
qrtpcr
analyt
sensit
specif
obtain
clinic
biolog
lab
set
sampl
uz
leuven
nation
refer
centr
diagnosi
right
reserv
reus
allow
without
permiss
certifi
peer
review
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
version
post
april
http
belgium
analys
laboratori
lhubulb
laboratoir
hospitali
universitair
bruxel
universitair
laboratorium
brussel
brussel
sampl
nasopharyng
swab
viral
transport
medium
analysi
protocol
ag
respistrip
follow
posit
patient
sampl
cycl
threshold
ct
ten
analys
duplic
weakli
posit
sampl
ct
analys
duplic
neg
patient
sampl
ten
analys
duplic
duplic
specimen
randomli
chosen
analys
observ
deliv
qualit
result
result
observ
diagnost
efficaci
ag
respistrip
evalu
compar
result
previous
obtain
fresh
nasopharyng
sampl
test
refer
qrtpcr
test
slightli
adapt
nrc
regard
qrtpcr
refer
test
total
nucleic
acid
extract
use
nuclisen
extract
easymag
lyon
franc
follow
addit
phocin
distemp
viru
pdv
intern
control
ic
pcr
amplif
perform
quantstudio
dx
thermo
fisher
scientif
use
slightli
adapt
egen
primer
probe
run
amplif
plot
analyz
interpret
use
quantstudio
test
develop
softwar
version
thermo
fisher
scientif
ict
assay
perform
follow
manufactur
instruct
use
high
contain
measur
biolog
safeti
cabinet
class
ii
sampl
analyt
perform
studi
consist
analyt
sensit
analyt
specif
reproduc
betweenobserv
disagr
observ
simultan
read
result
robust
crossreact
studi
experi
assess
reactiv
ag
respistrip
pathogen
conduct
lhubulb
depend
specimen
avail
consist
nasopharyng
aspir
sputa
clinic
residu
anonym
respiratori
sampl
patient
infect
test
concentr
pathogen
fluctuat
owe
avail
stock
clinic
specimen
highest
viru
load
select
user
friendli
studi
perform
accord
scandinavian
protocol
question
oper
respond
independ
checklist
right
reserv
reus
allow
without
permiss
certifi
peer
review
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
version
post
april
http
clinic
perform
studi
order
consid
implement
ag
respistrip
nation
diagnost
algorithm
urgent
multicentr
retrospect
studi
aim
assess
clinic
perform
rapid
assay
current
molecular
method
golden
standard
perform
overal
nasopharyng
sampl
patient
suspect
infect
attend
march
three
univers
laboratori
locat
belgium
test
follow
manufactur
instruct
assess
clinic
sensit
clinic
specif
posit
predict
valu
ppv
neg
predict
valu
npv
accuraci
order
propos
diagnost
algorithm
adapt
current
situat
uz
leuven
second
qrtpcr
method
perform
panther
fusion
pf
holog
san
diego
usa
open
accesstm
sarscov
analysi
analyt
protocol
follow
utm
nasopharyng
sampl
ad
pf
lysi
tube
mix
pipet
right
reserv
reus
allow
without
permiss
certifi
peer
review
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
version
post
april
http
load
instrument
follow
step
includ
total
nucleic
acid
extract
revers
transcript
realtim
pcr
automat
instrument
defin
ldtprotocol
use
myaccess
softwar
sarscov
assay
target
sarscov
gene
egen
primer
prober
slightli
adapt
corman
et
al
gene
amplif
plot
analys
system
softwar
use
paramet
defin
ldtprotocol
linear
regress
line
construct
normal
differ
ct
valu
found
two
method
use
uz
leuven
ypanther
fusion
xquantstudio
obtain
cutoff
posit
qrtpcr
result
group
per
categori
one
ct
match
frequent
qualit
interpret
obtain
ag
respistrip
least
qualit
interpret
found
posit
cutoff
studi
approv
ethic
board
erasm
chu
brugmann
chu
saintpierr
uz
leuven
chu
lieg
specif
approv
request
ec
leaflet
includ
follow
statement
given
admit
patient
accord
law
decemb
leftov
biolog
materi
collect
patient
standard
medic
manag
normal
destroy
diagnost
analysi
perform
use
valid
method
law
author
use
except
patient
express
opposit
still
aliv
presum
consent
risk
bottleneck
use
ag
respistrip
present
ishikawa
diagram
right
reserv
reus
allow
without
permiss
certifi
peer
review
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
version
post
april
http
doi
medrxiv
preprint
four
differ
assay
perform
assess
reactiv
antibodi
toward
sarscov
np
iiii
iv
nucleoprotein
antibodi
test
use
elisa
immobil
recnp
show
variou
reactivitiess
supplementari
digit
content
tabl
column
prior
use
antibodi
sandwich
detect
assay
antibodi
individu
test
abil
captur
andor
detect
target
recnp
ict
format
antibodi
thu
coat
onto
nitrocellulos
test
use
recnp
coupl
colloid
gold
bead
reactiv
record
base
visual
intens
ict
strip
suppl
tabl
column
ii
lastli
antibodi
coupl
colloid
gold
bead
migrat
ict
strip
recnp
immobil
result
record
suppl
tabl
column
iii
observ
reactiv
antibodi
elisa
assay
predict
abil
work
properli
captur
detect
reagent
ict
format
describ
previous
target
moreov
antibodi
detect
activ
detect
reagent
antibodi
b
c
column
iii
show
weak
good
captur
capabl
column
ii
compar
reactiv
recnp
overal
reactiv
higher
although
antibodi
initi
elicit
select
recnp
may
reflect
differ
protein
prepar
protocol
interestingli
antibodi
b
c
h
react
recnp
react
lead
hypothesi
antibodi
may
react
epitop
specif
recnp
present
sandwich
ict
assay
perform
combin
antibodi
work
captur
reagent
coat
nitrocellulos
antibodi
work
detect
reagent
goldlabel
ict
test
use
recnp
similar
concentr
test
combin
give
visibl
signal
assess
abil
detect
viru
suppl
tabl
assay
viru
perform
use
serial
dilut
cultur
supernat
rel
intens
observ
recnp
similar
prototyp
give
highest
signal
ag
respistrip
correspond
prototyp
characteris
analyt
perform
develop
ivd
medic
devic
right
reserv
reus
allow
without
permiss
certifi
peer
review
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
version
post
april
http
analyt
perform
studi
develop
phase
analyt
perform
first
perform
twofold
serial
dilut
limit
detect
defin
last
dilut
test
posit
test
independ
reader
assay
shown
detect
level
pgml
assay
test
supernat
vero
cell
infect
viru
found
assay
detect
pfuml
correspond
ct
valu
qrtpcr
assay
valid
clinic
biolog
lab
strip
use
analyt
studi
valid
except
two
analyt
sensit
patient
high
viral
load
ct
analyt
specif
tabl
crossreact
also
check
virus
cultur
supernat
coronavirus
sarscov
crossreact
observ
four
season
coronavirus
crossreact
observ
sarscov
expect
right
reserv
reus
allow
without
permiss
certifi
peer
review
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
version
post
april
http
user
friendli
satisfactori
inform
instruct
use
ifu
manufactur
time
factor
relat
preanalyt
analyt
phase
intern
extern
qualiti
control
unrel
kit
nt
avail
yet
overal
rate
qualiti
control
less
satisfactori
although
interpret
qualiti
control
line
integr
strip
satisfactori
even
control
line
show
weak
intens
user
friendli
evalu
relat
oper
show
satisfactori
rate
supplementari
digit
content
tabl
overal
clinic
sensit
clinic
specif
ppv
npv
accuraci
tabl
even
overal
sensit
detect
random
peopl
covidlik
symptom
present
hospit
subpopul
contagi
patient
highest
viral
load
ie
ct
test
detect
posit
patient
popul
ct
rang
cutoff
ag
respistrip
found
ct
cutoff
clinic
sensit
small
number
sampl
studi
symptomat
healthcar
worker
clinic
perform
show
sensit
specif
subpopul
base
result
clinic
perform
studi
diagnost
decis
algorithm
propos
figur
visual
risk
bottleneck
use
ag
respistrip
ishikawa
diagram
creat
consid
continu
risk
manag
fig
facil
clinic
biolog
laboratori
recommend
ishikawa
diagram
respond
highest
qualiti
assur
permit
lab
technician
handl
sampl
accord
biosafeti
recommend
right
reserv
reus
allow
without
permiss
certifi
peer
review
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
version
post
april
http
doi
medrxiv
preprint
extraordinari
spread
result
need
acceler
develop
rapid
accur
laboratori
diagnost
test
allow
fast
accur
detect
infect
patient
perspect
fast
nearpati
test
poct
could
repres
effect
diagnost
tool
prompt
clinic
quarantin
decis
besid
recent
certif
molecular
poct
xpert
xpress
genexxpert
cepheid
id
alerei
abbott
antigen
test
could
repres
valuabl
altern
especi
context
worldwid
reagent
instrument
shortag
alreadi
report
molecular
poct
next
prepeer
review
articl
report
fluoresc
immunochromatograph
assay
detect
nucleocapsid
protein
nasopharyng
swab
origin
research
report
accord
knowledg
first
one
describ
analyt
clinic
perform
nonfluoresc
ict
detect
antigen
nasopharyng
sampl
analyt
sensit
found
subpopul
high
viral
load
ct
analyt
specif
robust
ag
respistrip
show
promis
new
techniqu
addit
multicentr
retrospect
studi
confirm
promis
result
clinic
sensit
clinic
specif
clinic
sensit
subpopul
healthcar
worker
increas
subpopul
contagi
patient
high
viral
load
ct
note
clinic
valid
studi
sampl
collect
transport
media
first
process
qrtpcr
leftov
use
delay
ag
respistrip
sensit
may
impact
delay
sampl
collect
process
also
dilut
sampl
transport
media
may
affect
sensit
assay
clinic
valid
use
swab
sampl
directli
elut
assay
buffer
test
requir
assess
sensit
assay
poct
overal
sensit
found
analyt
valid
probabl
lower
overal
clinic
sensit
use
fresh
sampl
clinic
studi
sampl
analyt
studi
store
day
transport
room
temperatur
thaw
fridg
test
four
clinic
sampl
store
right
reserv
reus
allow
without
permiss
certifi
peer
review
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
version
post
april
http
intens
reaction
slightli
diminish
sampl
storag
studi
conduct
near
futur
accord
manufactur
ifu
nasopharyng
sampl
must
test
soon
possibl
collect
concord
need
rapid
diagnosi
pandem
situat
popul
see
differ
nasopharyng
swab
nasopharyng
aspir
recent
publish
data
report
high
viral
load
nasopharyng
midturbin
nare
specimen
infer
ict
could
also
good
sensit
specimen
previous
describ
virus
quantit
techniqu
evalu
swab
foam
polyest
swab
also
perform
reflect
crossreact
studi
number
sampl
analys
aureu
suffici
sputum
prescrib
sampl
type
manufactur
ifu
whether
fals
posit
sputum
due
matrix
effect
highviscos
aureu
clear
sputa
cystic
fibrosi
patient
possess
special
characterist
like
higher
viscos
multipathogen
cultur
prudent
stage
sputum
avoid
ag
respistrip
falseposit
result
exclud
sampl
type
whether
cystic
fibrosi
patient
exclud
analysi
ag
respistrip
directli
receiv
diagnosi
qrtpcr
clear
could
judici
advic
long
lack
evid
subpopul
high
viral
shed
ct
probabl
infecti
patient
clinic
sensit
notic
evalu
major
posit
patient
contain
high
viral
load
inde
posit
patient
clinic
perform
studi
ct
shi
et
al
mention
sever
respiratori
symptomat
stage
associ
high
viral
load
regard
result
test
accur
enough
overal
accuraci
implement
frame
integr
diagnost
strategi
combin
rapid
diagnost
test
base
antigen
detect
ag
respistrip
molecular
poct
diagnost
larg
autom
platform
latter
often
requir
tat
hour
figur
show
rapid
antigen
test
role
rapidli
take
measur
entri
emerg
depart
pandem
context
high
preval
thank
specif
antigen
testposit
patient
could
receiv
immedi
care
right
reserv
reus
allow
without
permiss
certifi
peer
review
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
version
post
april
http
antigen
testneg
patient
need
wait
ctscan
triag
result
qrtpcr
confirm
peak
epidem
approach
priorit
done
reliev
emerg
depart
situat
seek
implement
fast
hygien
measur
rapid
patient
care
defens
confirm
antigen
testposit
patient
qrtpcr
propos
diagnost
decis
algorithm
tat
could
restrain
minut
sampl
collect
patient
high
viral
load
fig
decis
algorithm
figur
show
potenti
clinic
use
ag
respistrip
patient
suspect
infect
thank
high
posit
predict
valu
howev
suspect
patient
suffer
sever
comorbid
could
benefit
molecular
poct
avail
higher
neg
predict
valu
desir
format
cost
molecular
poct
limit
larg
screen
strategi
especi
resourc
limit
distribut
delay
sinc
hospit
urgenc
plan
declar
belgium
healthcar
worker
focu
sever
criticallyil
patient
need
hospitalis
nasopharyng
sampl
suspect
patient
collect
present
emerg
depart
sampl
possess
probabl
highest
viral
load
closest
date
onset
symptom
refer
kinet
viral
load
shown
cao
et
al
reason
consid
ag
respistrip
could
relev
place
diagnost
algorithm
entri
emerg
depart
suspect
patient
risk
develop
sever
diseas
requir
hospitalis
accord
definit
possibl
case
describ
author
fig
decis
algorithm
would
prepar
clinic
laboratori
signific
increas
number
specimen
need
test
larg
area
countri
face
commun
transmiss
work
organ
propos
lab
rapid
result
posit
case
minut
recept
specimen
would
help
take
immedi
measur
prevent
spread
infecti
case
multisit
consolid
clinic
microbiolog
laboratori
model
lhubulb
diagnost
servic
provid
dedic
clinic
microbiolog
technologist
locat
central
lab
satellit
lab
ag
respistrip
handl
hour
day
technologist
chemistri
haematolog
crosstrain
compet
perform
interpret
result
rapid
test
sampl
neg
ict
result
transfer
central
laboratori
molecular
diagnosi
right
reserv
reus
allow
without
permiss
certifi
peer
review
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
version
post
april
http
postimplement
analysi
sampl
collect
lhubulb
st
march
th
april
patient
hospit
brussel
show
total
posit
test
result
detect
ag
respistrip
epidem
peak
day
screen
suspect
patient
propos
algorithm
allow
us
avoid
screen
qrtpcr
test
reduc
expens
qrtpcr
cost
also
consumpt
scarc
reagent
consum
even
cost
ag
respistrip
far
lower
cost
molecular
diagnost
method
budget
impact
studi
within
larger
health
econom
frame
question
whether
ctscan
would
still
need
triag
take
account
time
gain
implement
biosafeti
measur
earli
posit
result
ag
respistrip
help
clinician
entri
emerg
redirect
patient
faster
without
need
perform
ctscan
point
outpati
popul
sampl
due
lack
materi
diagnost
test
studi
need
test
ag
respistrip
outpati
popul
special
attent
healthcar
worker
frontlin
like
gener
practition
gp
pharmacist
regular
contact
mild
paucisymptomat
patient
one
could
consid
conjunct
public
health
author
isol
measur
could
eventu
focus
outpati
peopl
posit
ag
respistrip
result
subpopul
high
pretest
preval
suppos
could
becom
tool
manag
lockdown
implement
measur
would
depend
precipit
pandem
situat
possibl
start
supplement
prospect
outpati
studi
regard
prioriti
patient
popul
ag
respistrip
would
implement
first
consid
product
capac
new
method
highest
public
health
impact
reduc
transmiss
use
avail
resourc
furthermor
ag
respistrip
could
use
residenti
care
center
suppos
high
posit
ratio
close
commun
consid
risk
manag
bottleneck
mention
fig
ishikawa
diagram
show
ag
respistrip
readili
implement
clinic
laboratori
also
peripher
lab
procur
firstlin
diagnost
result
insid
outsid
hospit
gp
medic
specialist
countri
although
standard
oper
procedur
seem
written
use
devic
poct
caution
taken
wide
applic
gp
cabinet
three
reason
first
belgium
legal
framework
publish
right
reserv
reus
allow
without
permiss
certifi
peer
review
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
version
post
april
http
yet
design
respons
healthcar
worker
use
poct
outsid
hospit
environ
propos
legal
framework
draft
close
relat
gp
clinic
laboratori
guarante
traceabl
within
recogn
qualiti
manag
system
certif
compet
user
train
secondli
regard
biosecur
rule
handl
suspici
respiratori
sampl
absenc
biolog
safeti
cabinet
class
ii
gp
offic
gp
possess
protect
materi
like
biohazard
bin
steril
glove
dispos
lab
coat
lab
glass
mask
third
studi
record
mani
ag
respistrip
gave
weak
intens
control
test
line
user
friendli
studi
observ
mention
sourc
error
read
weakli
posit
ag
respistrip
due
difficulti
visual
colour
line
close
tube
better
visual
strip
good
light
crystal
tube
avail
lab
technician
sometim
open
test
tube
laminar
air
flow
cabinet
pull
strip
forcep
type
oper
would
never
accept
gp
environ
point
design
devic
strip
close
reaction
tube
r
continu
improv
matur
perspect
close
cassett
includ
close
sampl
handler
enhanc
visualis
test
line
reduc
risk
user
error
interpret
result
pilot
studi
evalu
applic
ag
respistrip
poct
devic
gp
offic
report
perform
obtain
relev
environ
intend
user
right
reserv
reus
allow
without
permiss
certifi
peer
review
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
version
post
april
http
studi
first
report
evalu
diagnost
efficaci
dispos
rapid
antigen
ag
respistrip
detect
expans
spread
worldwid
satisfi
perform
oper
util
promis
firstlin
diagnosi
pandem
situat
acceler
care
process
limit
qrtpcr
analysi
patient
found
neg
rapid
antigen
test
mention
propos
diagnost
algorithm
ag
respistrip
may
play
triag
role
peak
pandem
high
preval
especi
entri
emerg
depart
patient
present
high
viral
load
readili
implement
clinic
laboratori
procur
firstlin
diagnost
result
insid
outsid
hospit
gp
medic
specialist
contrari
applic
ivd
medic
devic
poct
gp
could
question
regard
matur
yet
avail
close
cassett
close
sampl
handler
legal
respons
concord
distribut
biosafeti
materi
especi
face
worldwid
ruptur
mask
summari
role
ag
respistrip
complementari
currentlyus
molecular
techniqu
right
reserv
reus
allow
without
permiss
certifi
peer
review
authorfund
grant
medrxiv
licens
display
preprint
perpetu
wish
thank
personnel
lhubulb
cori
bioconcept
daili
technic
assist
uz
leuven
nation
refer
centr
respiratori
pathogen
support
sciensano
grate
acknowledg
author
would
like
thank
patrick
murray
alex
van
belkum
gener
alway
posit
support
would
like
acknowledg
vivian
van
hoof
presid
poct
work
group
sciensano
work
dedic
healthcar
worker
patient
famili
affect
conflict
interest
statement
two
parti
merg
expertis
within
articl
intent
deliv
public
interest
public
health
system
one
hand
ivd
medic
devic
develop
investig
pascal
merten
henri
magein
justin
bouzet
work
cori
bioconcept
therefor
consid
scientif
investig
potenti
conflict
interest
even
nt
share
compani
thierri
leclipteux
also
involv
develop
test
ceo
cori
bioconcept
potenti
conflict
interest
hand
valid
describ
analyt
perform
studi
clinic
perform
studi
risk
manag
done
complet
independ
cori
bioconcept
without
conflict
financi
interest
scientif
investig
extern
cori
bioconcept
declar
conflict
interest
cori
bioconcept
offer
reagent
valid
cecertif
kit
diagnos
homeless
peopl
suspect
brussel
right
reserv
reus
allow
without
permiss
certifi
peer
review
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
version
post
april
certifi
peer
review
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
version
post
april
http
certifi
peer
review
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
version
post
april
http
certifi
peer
review
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
version
post
april
right
reserv
reus
allow
without
permiss
certifi
peer
review
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
version
post
april
http
